secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2025-03-05T23:59:59+00:00
Accession:  0000950170-25-033091
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health announces 1-for-17 reverse stock split effective March 7, 2025 to regain Nasdaq compliance
--------------------------------------------------------------------------------

- Reverse split at 1:17 ratio; effective 12:01 a.m. ET on March 7, 2025.
- Purpose: regain Nasdaq $1.00 minimum bid price after delisting notice received December 2024.
- Hearing before Nasdaq Panel held Feb 18, 2025; company awaits decision but expects split to aid listing.
- No fractional shares; any fractional interest rounded up to nearest whole share.
- Trading symbol TIVC unchanged; new CUSIP 888705308.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025033091/0000950170-25-033091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025033091/tivc-20250304.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-033091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer